Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid
Tóm tắt
We conducted a phase I/II clinical trial evaluating the sequential outpatient combination of S.C. recombinant human interleukin-2 (rIL-2; given at 10 MIU/m2 b.i.d. on days 3–5 of weeks 1 and 4 and at 5 MIU/m2 on days 1, 3, and 5 of weeks 2 and 3), s.c. recombinant human alpha-interferon (rIFN-α; given at 6 MIU/m2 on day 1 of weeks 1 and 4 and on days 1, 3, and 5 of weeks 2 and 3 and at 9 MIU/m2 on days 1, 3, and 5 of weeks 5–8), i.v. bolus 5-fluorouracil (5-FU; given at 1,000 mg/m2 once weekly during weeks 5–8), and i.v. bolus vinblastine (given at 6 mg/m2 once weekly during weeks 5 and 8) in conjunction with p.o. 13-cis-retinoic acid (13-C-RA; given at 35 mg/m2 daily during weeks 1–8). Therapy was always given in the outpatient setting. Grade 3 constitutional symptoms (malaise, chills, fevers, anorexia) were observed in 4%–8% of treatment cycles and required a 50% reduction in the doses of rIL-2 and rIFN-α. None of the patients experienced major 5-FU-related toxicities such as severe diarrhea and/or stomatitis; up to 20% of patients developed vinblastine-associated peripheral polyneuropathy, which was reversible after the cessation of therapy. 13-cis-Retinoic acid produced no significant side effect; no toxic death occurred. Among 24 patients with progressive metastatic disease, there were 4 complete remissions (lung, lymph nodes) and 6 partial remissions (lung, pleura, liver, lymph nodes, and peritoneal carcinosis), for an overall objective response rate of 42% (95% confidence interval, 22%–63%). An additional 13 patients achieved disease stabilization (54%). The median time to response was 3–4 months (range, up to 6 months); all responses are continuous. In summary, although the potential synergy of biochemotherapy plus 13-cis-retinoic acid requires further preclinical investigation, the current outpatient combination regimen (rIL-2, rIFN-a, 5-FU, vinblastine, and 13-C-RA) proved to be both safe and highly effective in patients with advanced metastatic renal-cell carcinoma. A current multiinstitutional prospectively randomized trial is comparing biochemotherapy with and without concomitant 13-C-RA against rIFN-α plus vinblastine.
Tài liệu tham khảo
Atzpodien J, Körfer A, Evers P, Francks C, Knüver-Hopf J, Lopez Hänninen E, Fischer M, Mohr H, Dallmann I, Hadam M, Poliwoda H, Kirchner H (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 2:18–26
Atzpodien J, Körfer A, Franks C, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-a2 in advanced human malignancies. Lancet 335:1509–1512
Atzpodien J, Kirchner H, Lopze Hänninen E, Körfer A, Fenner M, Menzel T, Deckert M, Franzke A, Jonas U, Poliwoda H (1993) European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 20:22–26
Atzpodien J, Kirchner H, Lopze Hänninen E, Deckert M, Franzke A, Poliwoda H (1994) European studies of interleukin-2 in metastatic renal cell cancer. Proc Am Soc Clin Oncol 13:773
Atzpodien J, Lopez Hänninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, Scholz HJ, Wilhelm S, Pielmeier T, Zakrzewski G, Blum G, Beier G, Müller G, Duensing S, Anton P, Allhoff E, Jonas U, Poliwoda H (1995) multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497–501
Crivellari D, Tumolo S, Frustaci S, Galligioni E, Figoli F, Lo Re G, Veronesi A, Monfardini S (1987) Phase II study of five day continuous infusion of vinblastine in patients with metastatic renal cell carcinoma. J Clin Oncol 45:1947–1956
Fossa SD, Martinell U, Otto G, Schneider H, Wander F, Oberling H, Bauer HW, Achtnicht U, Holdener E (1992) Recombinant interferon alfa-2 with or without vinblastine in metastatic renal cell carcinoma: results of a European multicenter phase III study. Ann Oncol 3:301–305
Harris DT (1984) Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 10:422–430
Krown SE (1985) Therapeutic options in renal cell carcinoma. Semin Oncol 12:13–17
Lopez Hänninen E, Fenner M, Kirchner H, Deckert M, Duensing S, Menzel T, Poliwoda H, Atzpodien J (1993) Limited efficacy of interferon-a and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. Cancer Biother 8:301–306
Maldazys JD, DeKernion JB (1986) Prognostic factors in renal cell carcinoma. J Urol 136:376–379
Motzer RJ, Murray-Law T, Schwartz L, Fischer P, Scher HI, Nanus DM (1994) Antitumor activity of interferon alfa-2 and 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 13:713
Patel NP, Lavengood RW (1977) Renal cell cancer: natural history and results of treatment. J Urol 119:722–726
Rosenberg SA, Yang CA, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907–913
Schomburg A, Kirchner H, Atzpodien J (1993) Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon-α: evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 119:745–755
Sleijfer DT, Janssen RA, Buter J, Vries EG de, Willemse PH, Mulder NH (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119–1123
Toma S, Monteghirfo S, Tasso P, Nicolo G, Spadini N, Palumbo R, Molina F (1994) Antiproliferative and synergistic effect of interferon alpha-2, retinoids and their association in established human cancer cell lines. Cancer Lett 82:209–216